Friday, May 26, 2017
Category : NEWS, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

This randomised, double-blind, placebo-controlled parallel trial aims to assess whether supplementation with the probiotic Lactobacillus rhamnosus HN001 can reduce the prevalence of gestational diabetes mellitus (GDM). Pregnant women with a personal or partner history of atopic disease received 6×109 CFU of L. rhamnosus (n=212) or placebo (n=211) daily.

 Lactobacillus rhamnosus HN001 associations with gestational diabetes mellitus (GDM)

Lactobacillus rhamnosus HN001 associations with gestational diabetes mellitus (GDM)

There was a trend towards lower relative rates (RR) of GDM in the L. rhamnosus group, 0.59 (95% CI 0.32, 1.08; p=0.08).

L. rhamnosus was associated with lower rates of GDM in women aged ≥35 years (RR 0.31; 95% CI 0.12, 0.81, p=0.009)(a) and women with a history of GDM (p=0.004) (c).

GDM prevalence was significantly lower in the L. rhamnosus group, 2.1% (95% CI 0.6, 5.2), v. 6.5% (95% CI 3.5, 10.9) in the placebo group (p=0.03).

Lactobacillus rhamnosus supplementation from 14 to 16 weeks’ gestation may reduce gestational diabetes mellitus prevalence, particularly among older women and those with previous gestational diabetes mellitus.


Wickens KL, Barthow CA, Murphy R, Abels PR, Maude RM, Stone PR, Mitchell EA, Stanley TV, Purdie GL, Kang JM, Hood FE, Rowden JL, Barnes PK, Fitzharris PF, Crane J. Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial. Br J Nutr. 2017 Apr 3:1-10.


This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…


More information on

Contact our Scientific & Regulatory experts at NUTRAVERIS, +33 2 96 76 54 87